Story perspectives

OMass Therapeutics Raises $310 Million for Congenital Adrenal Trials

By Drooid · Oct 15, 2026, 6:32 PM UTC · How we work

Summary

Story summary

OMass Therapeutics raised $310 million to advance clinical trials for a congenital adrenal hyperplasia drug.
OrbiMed raised nearly $3 billion for two new private-equity funds targeting health-care firms.
The OrbiMed funds will invest in health-care companies across the United States, Europe, and Asia.
A STAT reporter warned that China’s biotech boom could divert capital from U.S. startups, threatening U.S. venture-capital firms.

1 of 1

Story summary

OMass Therapeutics raised $310 million to advance clinical trials for a congenital adrenal hyperplasia drug.
OrbiMed raised nearly $3 billion for two new private-equity funds targeting health-care firms.
The OrbiMed funds will invest in health-care companies across the United States, Europe, and Asia.
A STAT reporter warned that China’s biotech boom could divert capital from U.S. startups, threatening U.S. venture-capital firms.